Daiichi and AZ have estimated that approximately 60% to 65% of HR-positive, HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultra-low.

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

The 27-year-old made jaws drop in her tiny white two-piece that contrasted with her bronzed complexion.

Panelists discuss how clinical trial data support the consistent efficacy of oral selective estrogen receptor degraders (SERDs) across diverse metastatic breast cancer subgroups—including patients ...

ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc ...

One word: slay.

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...